S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:TCONTRACON Pharmaceuticals Stock Price, Forecast & News

$1.70
-0.13 (-7.10 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.70
Now: $1.70
$1.85
50-Day Range
$1.65
MA: $1.87
$2.05
52-Week Range
$0.95
Now: $1.70
$6.10
Volume234,810 shs
Average Volume455,721 shs
Market Capitalization$9.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Read More
TRACON Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCON
CUSIPN/A
Phone858-550-0780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3 million
Book Value$0.67 per share

Profitability

Net Income$-22,670,000.00

Miscellaneous

Employees26
Market Cap$9.35 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$1.70
-0.13 (-7.10 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

How has TRACON Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TCON stock has increased by 20.6% and is now trading at $1.70.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of TRACON Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TRACON Pharmaceuticals
.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for TRACON Pharmaceuticals
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.04.
View TRACON Pharmaceuticals' earnings history
.

What price target have analysts set for TCON?

1 Wall Street analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 135.3% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals
.

Has TRACON Pharmaceuticals been receiving favorable news coverage?

Headlines about TCON stock have trended neutral this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about TRACON Pharmaceuticals
.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 121,500 shares, an increase of 66.4% from the June 30th total of 73,000 shares. Based on an average daily trading volume, of 409,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.5% of the shares of the company are short sold.
View TRACON Pharmaceuticals' Short Interest
.

Who are some of TRACON Pharmaceuticals' key competitors?

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Opko Health (OPK), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), T2 Biosystems (TTOO), Actinium Pharmaceuticals (ATNM), Corbus Pharmaceuticals (CRBP) and MEI Pharma (MEIP).

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:
  • Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 55)
  • Mr. Scott B. Brown, VP & Head of Fin.
  • Dr. Sharon Real, Exec. VP of Product Devel. (Age 55)
  • Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 42)
  • Ms. Suzy Benedict, Sr. VP of Regulatory Affairs

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.70%) and Wedbush Securities Inc. (0.47%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Cross-Border Opportu Puissance, Mark C Wiggins and Saundra L Pelletier.
View institutional ownership trends for TRACON Pharmaceuticals
.

Which major investors are buying TRACON Pharmaceuticals stock?

TCON stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and Wedbush Securities Inc.. Company insiders that have bought TRACON Pharmaceuticals stock in the last two years include Charles Theuer, Cross-Border Opportu Puissance, Mark C Wiggins, and Saundra L Pelletier.
View insider buying and selling activity for TRACON Pharmaceuticals
.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $1.70.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $9.35 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-22,670,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.